NCT07015762View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 14, 2025

Primary Completion Date

May 20, 2026

Study Completion Date

May 20, 2026

Conditions
Atopic Dermatitis
Interventions
DRUG

IBI3002

Participants with AD will receive IBI3002 at the corresponding dose and dosing interval.

DRUG

Placebo

Participants with AD will receive placebo at the corresponding volume and dosing interval.

Trial Locations (1)

215000

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT07015762 - A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis | Biotech Hunter | Biotech Hunter